Validated LC‐MS/MS Method for Quantification and Pharmacokinetic Analysis of Talazoparib and Enzalutamide in Rats
Biomedical Chromatography · 2026
DOI: 10.1002/bmc.70381 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2026. Verfasst von Rajesh Guntupalli und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Biotechnology and Pharmaceutical Sciences, Vignan's Foundation for Science, Technology & Research, G…. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Phenylthiohydantoin, Liquid Chromatography-Mass Spectrometry, Phthalazines. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
The FDA has approved Talazoparib and Enzalutamide for metastatic castration‐resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene mutations, based on the TALAPRO‐2 Phase 3 trial. This study developed and validated an LC‐MS/MS method for simultaneous quantification of Talazoparib and Enzalutamide in rat plasma using Apalutamide as the internal standard. Chromatographic separation was achieved with a 70:30 (v/v) acetonitrile–0.1% formic acid system, 10 min runtime, and 1.0 mL/min flow rate. Retention times were 4.13 min (Talazoparib), 5.31 min (Enzalutamide), and 7.89 min (Apalutamide). Detection was performed in positive ionization mode using MRM transitions: m / z 381.35 → 240.56, 465.44 → 305.24, and 478.44 → 285.10, respectively. The method was linear over 0.05–2 ng/mL for Talazoparib and 4–160 ng/mL for Enzalutamide ( r 2 > 0.999). Accuracy and precision were within ±15%–20%, and recovery exceeded 98%. In pharmacokinetic studies on male Wistar rats, Talazoparib showed a C max of 0.88 ng/mL at 3 h and an AUC 0− t of 20 ng·h/mL, while Enzalutamide exhibited a C max of 76.18 ng/mL at 1 h and an AUC 0− t of 1702 ng·h/mL; both had 24 h half‐lives. The validated method enables sensitive, rapid, and reliable bioanalysis for preclinical pharmacokinetic evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, School of Biotechnology and Pharmaceutical Sciences, Vignan's Foundation for Science, Technology & Research, Guntur, Andhra Pradesh, India.
- Department of Pharmaceutical Analysis, Vignan Pharmacy College, Guntur, Andhra Pradesh, India.
ORCID-Profile: Rajesh Guntupalli, Panchumarthy Ravisankar, Sathish Kumar Konidala
Zitieren
APA
Guntupalli, R., Ravisankar, P., & Konidala, S. K. (2026). Validated LC‐MS/MS Method for Quantification and Pharmacokinetic Analysis of Talazoparib and Enzalutamide in Rats. Biomedical Chromatography. https://doi.org/10.1002/bmc.70381
Vancouver
Guntupalli R, Ravisankar P, Konidala SK. Validated LC‐MS/MS Method for Quantification and Pharmacokinetic Analysis of Talazoparib and Enzalutamide in Rats. Biomedical Chromatography. 2026. doi:10.1002/bmc.70381
BibTeX
@article{Guntupalli2026,
author = {Guntupalli, Rajesh and Ravisankar, Panchumarthy and Konidala, Sathish Kumar},
title = {Validated LC‐MS/MS Method for Quantification and Pharmacokinetic Analysis of Talazoparib and Enzalutamide in Rats},
journal = {Biomedical Chromatography},
year = {2026},
doi = {10.1002/bmc.70381}
}
EUVIMED